Compare CDMOs specializing in small molecule API synthesis from route scouting through commercial manufacturing. Filter by chemistry capabilities, scale, and regulatory approvals.
516 companies listed
For a small molecule API, the synthetic route is the program. A CDMO's process chemists decide how you get from raw materials to drug substance: how many steps, what yield, and which impurities you'll spend the next two years explaining to regulators. Route scouting and development are where a strong API partner earns its fee. Crystallization is the part buyers underestimate. It controls polymorphic form and particle size, and a polymorph surprise during scale-up has delayed more filings than most people admit. So probe the chemistry. Have they run your reaction types (hydrogenation, cryogenic steps, flow chemistry) at kilo-lab through metric-ton scale? Is the API high-potency, needing OEB4/5 containment? Do they have ICH Q11 filings and a defensible regulatory starting material strategy? 516 CDMOs here list small molecule API synthesis. Compare them on chemistry, scale, and regulatory experience.
Active Pharmaceutical Ingredient (API) manufacturing is the chemical synthesis of the drug substance itself. For small molecules, this involves multi-step organic chemistry from raw materials to the final API, requiring expertise in reaction chemistry, purification, crystallization, and process optimization.
Process chemistry determines project success. A strong CDMO identifies the most efficient synthetic route, optimizes reaction conditions for yield and purity, and develops a process that scales reliably from gram to metric ton quantities. Crystallization expertise is particularly critical for controlling polymorphic form and particle size distribution.
India
Syngene International is a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated services spanning drug discovery through commercial manufacturing for both small and large molecules. The company has long-term research collaborations with Bristol Myers Squibb (extended until 2035) and Amgen. Syngene recently opened its first US manufacturing facility in Rockville, Maryland, and added a bioconjugation suite in Bengaluru for end-to-end ADC development. The company has 20 kL single-use drug substance capacity for biologics.
Netherlands
TAPI (Teva Active Pharmaceutical Ingredients) is the API division of Teva Pharmaceutical Industries, positioned as the world's leading international supplier of APIs with 350+ products in their portfolio. They offer integrated API and CDMO services, leveraging 85+ years of API development and manufacturing expertise. TAPI provides customized solutions including complex API development, peptide manufacturing (including GLP-1 capability), and end-to-end manufacturing. They have a partnership with Antheia for biosynthetic pharmaceutical ingredients and with Sagimet Biosciences for resmetirom API. TAPI operates globally with multiple manufacturing sites.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.